Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-21
2010-10-26
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S277000
Reexamination Certificate
active
07820695
ABSTRACT:
Disclosed herein are pharmaceutical compositions comprising an inverse serotonin receptor agonist or a serotonin receptor antagonist and an anti-psychotic agent. Disclosed herein are also methods of treating psychotic disorders using the disclosed pharmaceutical compositions.
REFERENCES:
patent: 3983234 (1976-09-01), Sayers
patent: 4138492 (1979-02-01), Noverola et al.
patent: 4255432 (1981-03-01), Kluge et al.
patent: 4332804 (1982-06-01), Clark
patent: 4353900 (1982-10-01), Clark
patent: 4353901 (1982-10-01), Clark
patent: 4367232 (1983-01-01), Boix-Igleasias et al.
patent: 4853394 (1989-08-01), King et al.
patent: 5025013 (1991-06-01), Barreau et al.
patent: 5214055 (1993-05-01), Peglion et al.
patent: 5216165 (1993-06-01), Mobilio et al.
patent: 5461066 (1995-10-01), Gericke et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5621010 (1997-04-01), Sueda et al.
patent: 5707798 (1998-01-01), Brann
patent: 5795894 (1998-08-01), Shue et al.
patent: 5869488 (1999-02-01), Shue et al.
patent: 5877173 (1999-03-01), Olney et al.
patent: 5912132 (1999-06-01), Brann
patent: 5955281 (1999-09-01), Brann
patent: 6107324 (2000-08-01), Behan et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6150393 (2000-11-01), Behan et al.
patent: 6358698 (2002-03-01), Weiner et al.
patent: 6479480 (2002-11-01), Moyes et al.
patent: 6756393 (2004-06-01), Andersson et al.
patent: 6815458 (2004-11-01), Andersson et al.
patent: 6911452 (2005-06-01), Schlienger
patent: 7022698 (2006-04-01), Hamied et al.
patent: 7041667 (2006-05-01), Armour et al.
patent: 7115634 (2006-10-01), Thurieau et al.
patent: 7253186 (2007-08-01), Andersson et al.
patent: 2002/0004513 (2002-01-01), Andersson et al.
patent: 2002/0156068 (2002-10-01), Behan et al.
patent: 2002/0165225 (2002-11-01), Hamied et al.
patent: 2004/0006081 (2004-01-01), Burrows et al.
patent: 2004/0106600 (2004-06-01), Andersson et al.
patent: 2004/0213816 (2004-10-01), Weiner et al.
patent: 2005/0014757 (2005-01-01), Andersson et al.
patent: 2005/0148018 (2005-07-01), Weiner et al.
patent: 2005/0244862 (2005-11-01), Brann
patent: 2005/0256108 (2005-11-01), Schlienger
patent: 2006/0094758 (2006-05-01), Andersson et al.
patent: 2006/0106063 (2006-05-01), Thygesen et al.
patent: 2006/0111399 (2006-05-01), Thygesen et al.
patent: 2006/0194778 (2006-08-01), Andersson et al.
patent: 2006/0194834 (2006-08-01), Andersson et al.
patent: 2006/0199794 (2006-09-01), Schlienger
patent: 2006/0199818 (2006-09-01), Andersson et al.
patent: 2006/0199842 (2006-09-01), Weiner et al.
patent: 2006/0205710 (2006-09-01), Schlienger et al.
patent: 2006/0205722 (2006-09-01), Andersson et al.
patent: 2006/0205780 (2006-09-01), Thygesen et al.
patent: 2006/0205781 (2006-09-01), Thygesen et al.
patent: 2006/0264465 (2006-11-01), Weiner et al.
patent: 2006/0264466 (2006-11-01), Weiner et al.
patent: 2006/0286610 (2006-12-01), Brann
patent: 2006/0292606 (2006-12-01), Brann
patent: 984843 (1976-03-01), None
patent: 0 005 318 (1979-11-01), None
patent: 0 061 333 (1982-09-01), None
patent: 0 379 441 (1990-07-01), None
patent: 0 548 015 (1993-06-01), None
patent: 0 260 070 (1993-08-01), None
patent: 0 625 507 (1994-11-01), None
patent: 1 656 938 (2006-05-01), None
patent: 2802206 (2001-06-01), None
patent: 157325 (1998-03-01), None
patent: 51052176 (1976-05-01), None
patent: 5208517 (1977-07-01), None
patent: WO 94/27967 (1994-12-01), None
patent: WO 97/08166 (1997-03-01), None
patent: WO 97/11940 (1997-04-01), None
patent: WO 97/38665 (1997-10-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/11128 (1998-03-01), None
patent: WO 98/17646 (1998-04-01), None
patent: WO 98/44921 (1998-10-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/52927 (1999-10-01), None
patent: WO 00/23076 (2000-04-01), None
patent: WO 00/56335 (2000-09-01), None
patent: WO 00/59497 (2000-10-01), None
patent: WO 00/69810 (2000-11-01), None
patent: WO 01/44191 (2001-06-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/66521 (2001-09-01), None
patent: WO 01/87839 (2001-11-01), None
patent: WO 02/24649 (2002-03-01), None
patent: WO 02/076464 (2002-10-01), None
patent: WO 02/079186 (2002-10-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/057698 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/062206 (2003-07-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/086400 (2003-10-01), None
patent: WO 04/000808 (2003-12-01), None
patent: WO 04/000808 (2003-12-01), None
patent: WO 2004/009549 (2004-01-01), None
patent: WO 2004/039322 (2004-05-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064738 (2004-08-01), None
patent: WO 2004/064753 (2004-08-01), None
patent: WO 2004/072034 (2004-08-01), None
patent: WO 2005/053796 (2005-06-01), None
patent: WO 2005/063254 (2005-07-01), None
patent: WO 2005/112927 (2005-12-01), None
patent: WO 2006/036874 (2006-04-01), None
patent: WO 2006/037043 (2006-04-01), None
patent: WO 2006/104826 (2006-10-01), None
Benfield P, Heel RC, Lewis SP, “Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness,” Drugs, 1986, 32(6), pp. 481-508.
R&D Focus Drug News (Nov. 12, 2001).
Goodman and Gilman, The Pharmacological Basis of Therapeutics, McGraw Hill, 1996, 9th ed., p. 434-435.
Adam, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers.Psychopharmacology, 99:219-221.
Adell, et al. 2005. Strategies for producing faster acting antidepressants.Drug Discovery Today, 10(8):578-585.
Akin, et al. 2004. Decreased serotonin 5-HT2Areceptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients.Neuropsychopharmacology, 29:2081-2087.
Alvisi, N. 1892. Sulla formazione di derivati pirazolici dalle dicloridrine e dalla tribromidrina della glicerina ordinaria,Gazz. Chem. Ital.22:158-168.
Antilla, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines.Organic Letters, 3(13):2077-2079.
Antilla, et al. 2002. The copper-catalyzedN-arylation of indoles.J. Am. Chem. Soc., 124:11684-11688.
Archibald, et al., 1974 “Benzamidopiperdines. 2. Heterocyclic Compounds Related to Indoramin”J. Medicinal Chemistry, 17(7):736-739.
Archibald, et al., 1974 “Benzamidopiperdines. 3. Heterocyclic Compounds Related to Indoramin” J. Medicinal Chemistry, 17(7):-739-744.
Archibald, et al., 1974 “1,4-Bis-(2-indol-3-ylethyl)piperdines” J. Medicinal Chemistry, 17(7):-745-747.
Artico, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase.Eur. J. Med. Chem., 27:219-228.
Bakshi, et al. 1994. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.The Journal of Pharmacology and Experimental Therapeutics, 271(2):787-794.
Barchas, J. 1973.Serotonin and Behavior.New York: Academic Press.
Barnes, et al. 1999. A review of central 5-HT receptors and their function.Neuropharmacology, 38:1083-1152.
Barr, et al. 1997. Agonist-independent activation of Gzby the 5-hydroxytryptamine1Areceptor co-expressed inSpodoptera frugiperdacells.The Journal of Biological Chemistry, 272(52):32979-32987.
Bassus, et al. 1974. Psychotropies potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydrooxazinone douées d'activité neuroleptique.Eur. J. Med. Chem.—Chimica Therapeutica, 9(4):416-423.
Bennett, et al. 1993. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms.Neurology, 43:1551-1555.
Bhatia, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2H,4H-tetrahydro-1,2,4-triazin-3-ones.J. Med. Chem., 39:3938-3950.
Biagi, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis in vitro.Farmaco Ed. Sci., 43:597-612.
Bibbiani, et al. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkin
Brann Mark R.
Davis Robert E.
Weiner David M.
ACADIA Pharmaceuticals Inc.
Javanmard Sahar
Jones Day
Padmanabhan Sreeni
LandOfFree
Selective serotonin receptor inverse agonists as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective serotonin receptor inverse agonists as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective serotonin receptor inverse agonists as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175419